{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:30:48Z","timestamp":1787589048018,"version":"build-2736575974"},"reference-count":0,"publisher":"Canadian Society of Healthcare-Systems Pharmacy","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can J Hosp Pharm"],"abstract":"<jats:p>Background: The antibiotic cefazolin is commonly used in pregnancy, as first-line prophylaxis for cesarean section wounds or as an alternative to penicillin for prophylaxis against group B Streptococcus. About 10% of people report a penicillin allergy, and clinicians have historically avoided the use of \u03b2-lactams (including cefazolin) in these individuals. Instead, they have used non-\u03b2-lactams, which can lead to poorer maternal outcomes.\nObjective: To evaluate the safety of cefazolin in pregnant patients with a documented history of penicillin allergy.\nMethods: This retrospective cohort study included all pregnant patients with a documented penicillin allergy at the time of receiving their first dose of cefazolin at a large tertiary care hospital (January 2016 to August 2021). Descriptive statistics were calculated.\nResults: A total of 179 patients were included in the analysis. Most (175 [97.8%]) had no allergic adverse event after receiving cefazolin. Two patients (1.1%) experienced immunoglobulin E (IgE)\u2013mediated hives, and 2 patients (1.1%) experienced non\u2013IgE-mediated rashes. No patients experienced anaphylaxis, and no patients with a documented history of anaphylaxis to penicillins experienced an allergic adverse event related to cefazolin. All 4 patients who experienced an allergic adverse event were discharged with no readmission to the study institution associated with the allergic adverse event.\nConclusion: No patients with a documented history of anaphylaxis to penicillin experienced an allergic adverse event upon receiving cefazolin. Cefazolin was safely given to pregnant people with a history of penicillin allergy.\nKeywords: cefazolin, obstetrics, pregnancy, penicillin allergy, \u03b2-lactam allergy\nR\u00c9SUM\u00c9\nContexte : La c\u00e9fazoline est un antibiotique couramment utilis\u00e9 pendant la grossesse comme prophylaxie de premi\u00e8re intention pour les plaies op\u00e9ratoires de c\u00e9sarienne ou comme solution de rechange \u00e0 la p\u00e9nicilline pour la prophylaxie contre le streptocoque du groupe B. Environ 10 % des personnes d\u00e9clarent \u00eatre allergiques \u00e0 la p\u00e9nicilline et les cliniciens ont par le pass\u00e9 \u00e9vit\u00e9 l\u2019utilisation des \u03b2-lactamines (y compris la c\u00e9fazoline) chez ces patients, pr\u00e9f\u00e9rant des antibiotiques non \u03b2-lactamines, ce qui peut entra\u00eener des r\u00e9sultats maternels moins favorables.\nObjectif : \u00c9valuer l\u2019innocuit\u00e9 de la c\u00e9fazoline chez les patientes enceintes ayant des ant\u00e9c\u00e9dents attest\u00e9s d\u2019allergie \u00e0 la p\u00e9nicilline.\nM\u00e9thodologie : Cette \u00e9tude de cohorte r\u00e9trospective incluait toutes les patientes enceintes ayant une allergie attest\u00e9e \u00e0 la p\u00e9nicilline au moment de recevoir la premi\u00e8re administration de c\u00e9fazoline dans un grand h\u00f4pital tertiaire (de janvier 2016 \u00e0 ao\u00fbt 2021). Des statistiques descriptives ont \u00e9t\u00e9 calcul\u00e9es.\nR\u00e9sultats : Un total de 179 patientes ont \u00e9t\u00e9 incluses dans l\u2019analyse. La plupart (175 [97,8 %]) n\u2019avaient connu aucun ant\u00e9c\u00e9dent d\u2019\u00e9v\u00e9nement ind\u00e9sirable allergique li\u00e9 \u00e0 la c\u00e9fazoline. Deux patientes (1,1 %) ont eu de l\u2019urticaire m\u00e9di\u00e9e par les immunoglobulines E (IgE), et des \u00e9ruptions non m\u00e9di\u00e9es par les IgE se sont produites chez deux autres (1,1 %). Aucune patiente n\u2019a connu d\u2019anaphylaxie, et aucune ayant des ant\u00e9c\u00e9dents attest\u00e9s d\u2019anaphylaxie aux p\u00e9nicillines n\u2019a connu d\u2019\u00e9v\u00e9nement allergique li\u00e9 \u00e0 la c\u00e9fazoline. Les 4 patientes ayant connu un \u00e9v\u00e9nement ind\u00e9sirable allergique ont quitt\u00e9 l\u2019\u00e9tablissement \u00e9tudi\u00e9 li\u00e9 \u00e0 cet \u00e9v\u00e9nement sans y \u00eatre r\u00e9admises.\nConclusion : Aucune patiente ayant des ant\u00e9c\u00e9dents attest\u00e9s d\u2019anaphylaxie \u00e0 la p\u00e9nicilline n\u2019a v\u00e9cu d\u2019\u00e9v\u00e9nement ind\u00e9sirable allergique apr\u00e8s avoir re\u00e7u de la c\u00e9fazoline. La c\u00e9fazoline a \u00e9t\u00e9 administr\u00e9e en toute s\u00e9curit\u00e9 aux personnes enceintes ayant une allergie \u00e0 la p\u00e9nicilline.\nMots-cl\u00e9s : c\u00e9fazoline, obst\u00e9trique, grossesse, allergie \u00e0 la p\u00e9nicilline, allergie aux \u03b2-lactamines<\/jats:p>","DOI":"10.4212\/cjhp.3774","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:10:01Z","timestamp":1759939801000},"source":"Crossref","is-referenced-by-count":1,"title":["Safety of Cefazolin in Pregnant Patients with Documented Penicillin Allergy: A Retrospective Cohort Study"],"prefix":"10.4212","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0997-0137","authenticated-orcid":false,"given":"Caitlin","family":"Chew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6801-1249","authenticated-orcid":false,"given":"Roxane","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Elwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Paquette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2732","published-online":{"date-parts":[[2025,10,8]]},"container-title":["Canadian Journal of Hospital Pharmacy"],"original-title":[],"link":[{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/download\/3774\/5736","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/download\/3774\/5741","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/download\/3774\/5736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:10:02Z","timestamp":1759939802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/view\/3774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":0,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,10,8]]}},"URL":"https:\/\/doi.org\/10.4212\/cjhp.3774","relation":{},"ISSN":["1920-2903","0008-4123"],"issn-type":[{"value":"1920-2903","type":"electronic"},{"value":"0008-4123","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"article-number":"e3774"}}